A pharmaceutical company submits a Biologics License Application (BLA) instead of an NDA when the product is:
-
A
A small-molecule chemical synthesized in a laboratory
-
B
A large-molecule product derived from living cells or organisms such as a vaccine or monoclonal antibody
-
C
A generic version of an existing prescription drug
-
D
A medical device that delivers a drug transdermally